These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27823574)

  • 1. Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
    Attia ; Ahmed H; Gadelkarim M; Morsi M; Awad K; Elnenny M; Ghanem E; El-Jaafary S; Negida A
    CNS Neurol Disord Drug Targets; 2017; 16(2):169-175. PubMed ID: 27823574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Negida A; Menshawy A; El Ashal G; Elfouly Y; Hani Y; Hegazy Y; El Ghonimy S; Fouda S; Rashad Y
    CNS Neurol Disord Drug Targets; 2016; 15(1):45-53. PubMed ID: 26553164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.
    Mo JJ; Liu LY; Peng WB; Rao J; Liu Z; Cui LL
    BMC Neurol; 2017 Jun; 17(1):105. PubMed ID: 28577542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creatine for Parkinson's disease.
    Xiao Y; Luo M; Luo H; Wang J
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009646. PubMed ID: 24934384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
    Abdelalem Aziz Ahmed M
    F1000Res; 2019; 8():2078. PubMed ID: 32431802
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
    Jiang DQ; Li MX; Jiang LL; Chen XB; Zhou XW
    Aging Clin Exp Res; 2020 May; 32(5):769-779. PubMed ID: 31175606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
    Márquez-Cruz M; Díaz-Martínez JP; Soto-Molina H; De Saráchaga AJ; Cervantes-Arriaga A; Llorens-Arenas R; Rodríguez-Violante M
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):97-102. PubMed ID: 26731410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis.
    Negida A; Ghaith HS; Fala SY; Ahmed H; Bahbah EI; Ebada MA; Aziz MAE
    Neurol Sci; 2021 Aug; 42(8):3135-3143. PubMed ID: 34014397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
    Cai JP; Chen WJ; Lin Y; Cai B; Wang N
    Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.